On the HCPLive Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.
January 21st 2025
The FDA approved esketamine (SPRAVATO) nasal spray as the first monotherapy for adults with TRD, showing rapid efficacy at 4 weeks.